Variable Interval Versus Set Interval Aflibercept for DME (EVADE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02392364 |
Recruitment Status :
Completed
First Posted : March 19, 2015
Last Update Posted : January 3, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cystoid Macular Edema Diabetic Macular Edema | Drug: Intravitreal Aflibercept Injection | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) |
Actual Study Start Date : | April 15, 2015 |
Actual Primary Completion Date : | November 15, 2018 |
Actual Study Completion Date : | November 15, 2018 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Variable Treatment Dosing Arm
Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
|
Drug: Intravitreal Aflibercept Injection |
Active Comparator: Monthly Treatment Arm
Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
|
Drug: Intravitreal Aflibercept Injection |
- BCVA Change [ Time Frame: Week 0 to Week 52 ]Change in mean BCVA from baseline to week 52

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults 18 years and older with Type 1 or Type 2 diabetes mellitus
- Patients with diabetic macular edema involving the center of the macular in the study eye (CST must measure at least 350µm on Heidelberg SDOCT, or 333µm on Cirrus SDOCT)
- Decrease in vision determined to be primarily due to DME in the study eye
- BCVA ETDRS letter score 78 to 24 (20/32 to 20/320) in the study eye
- Willing and able to comply with clinical visits and study related procedures
- Willing and able to provide signed informed consent
Exclusion Criteria:
- History of vitreoretinal surgery in the study eye
- Laser photocoagulation (panretinal or macular) in the study eye within 90 days of baseline
- Previous use of intraocular or periocular corticosteroids in the study eye within 90 days of baseline
- History of intravitreal anti-VEGF treatments in the study within 90days prior to baseline (not including prior intravitreal aflibercept injection [see exclusion criteria #5])
- Any history of intravitreal aflibercept
- Active proliferative diabetic retinopathy (PDR) in the study eye
- History of idiopathic or autoimmune uveitis in the study eye
- Cataract surgery in the study eye within 90 days of baseline
- Aphakia in the study eye
- Yttrium aluminum garnet (YAG) capsulotomy in the study eye within 30 days of baseline
- Any intraocular surgery in the study eye within 90 days of day 1
- Vitreomacular traction or epiretinal membrane in the study eye that is thought to affect central vision
- Current iris neovascularization, vitreous hemorrhage, or traction retinal detachment in the study eye
- Pre-retinal fibrosis involving the macula in the study eye
- Uncontrolled glaucoma (defined as any patient who has had filtration surgery in the past, or likely to need filtration surgery in the future, or has IOP ≥30mmHg)
- Myopia of a spherical equivalent prior to any possible refractive or cataract surgery of ≥-8 diopters
- Concurrent disease in the study eye, other than DME, that could compromise BCVA, require medical or surgical intervention during the study period, or could confound interpretation of the results (including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause)
- Ocular media of insufficient quality to obtain fundus and SDOCT images
- Current treatment for a systemic infection
- Administration of systemic anti-angiogenic agents within 180 days of baseline
- Uncontrolled diabetes mellitus, in the opinion of the investigator
- Uncontrolled blood pressure (define as systolic >180mmHg, or diastolic >110mmHg while patient is sitting)
- History of CVA or MI within 180 days of baseline
- Renal failure requiring dialysis or renal transplant
- Known serious allergy to fluorescein
- Participation in an investigational study within 30 days prior to baseline that involved treatment with any drug (excluding vitamins and minerals) or device
- Any women who are pregnant, breast-feeding, or attempting to become pregnant
- Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02392364
United States, California | |
California Retina Consultants - Bakersfield | |
Bakersfield, California, United States, 93039 | |
California Retina Consultants - Santa Barbara Office | |
Santa Barbara, California, United States, 93103 |
Principal Investigator: | Dilsher S Dhoot, MD | California Retina Consultants |
Responsible Party: | California Retina Consultants |
ClinicalTrials.gov Identifier: | NCT02392364 |
Other Study ID Numbers: |
2014-01-CRC |
First Posted: | March 19, 2015 Key Record Dates |
Last Update Posted: | January 3, 2019 |
Last Verified: | January 2019 |
Retinal Degeneration Retinal Diseases Macular Edema Edema Macular Degeneration Eye Diseases Aflibercept |
Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents |